|
08:00
|
Registration and Morning Refreshments
|
|
09:00
|
Welcome Address
|
|
09:15
|
Keynote Lecture
Gidi Rechavi, Sheba Cancer Research Center, Israel
Epitranscriptomics is entering the therapeutic arena
|
|
10:00
|
Shulamit Levenberg, Technion, Israel
Engineered skeletal muscle constructs overexpressing GLUT4 for type 2 diabetes treatment
|
|
10:20
|
Rotem Karni, The Hebrew University of Jerusalem, Israel
Modulating RNA processing for therapy
|
|
10:40
|
Batsheva Kerem, The Hebrew University of Jerusalem, Israel
Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach
|
|
11:00
|
Coffee Break
|
|
11:30
|
Eyal Banin, The Hebrew University of Jerusalem / Hadassah Medical Center, Israel
Gene Augmentation Therapy for Achromatopsia Caused by Mutations in the CNGA3 Gene: The Journey from Molecular Genetics to Clinical Application
|
|
11:50
|
Orit Shefi, Bar-Ilan University, Israel
Neuro-engineering tools for nerve regeneration
|
|
12:10
|
Lior Gepstein, Technion, Israel
Gene and cell therapy approaches for cardiac disorders
|
|
12:30
|
Edward Wong, GenScript
Cancer Immunotherapy: The next generation of cancer treatment
|
|
12:50
|
Short Talk: Amnon Peled, Hadassah Hebrew University Hospital, Israel
Targeting cancer using super activated killer cells (SAK)
|
| 12:56 |
Short Talk: Liron Elkouby, NOGA Therapeutics, Israel
Development of safe and effective lentiviral vector for gene therapy of X-linked Agammaglobulinemia (XLA) utilizing endogenous Bruton's Tyrosine Kinase (BTK) regulation
|
| 13:02 |
Short Talk: Daniel Allen, Bar-Ilan University, Israel
High-throughput imaging of CRISPR- and rAAV-induced DNA damage response in human Hematopoietic Stem and Progenitor cells
|
| 13:08 |
Short Talk: Ignacio Mastandrea, Tel Aviv University, Israel
Boosting CAR T Cell efficacy by modulation of the tumor microenvironment in Glioblastoma
|
| 13:14 |
Short Talk: Alessio D. Nahmad, Tel Aviv University, Israel
Frequent CRISPR-Cas9 induced Aneuploidy in primary human T Cells
|
| 13:20 |
Short Talk: Yaara Ohayon, Sheba Medical Center, Israel
Establishment of a national cost-effective cGMP manufacturing infrastructure to support Israel novel gene therapies
|
| 13:25 |
Yaron Ramati, Gilboa, Israel
Development and regulation of advanced therapies
|
|
13:30
|
Lunch and Poster Session
|
|
15:00
|
Karen B. Avraham, Tel Aviv University, Israel
Rescuing hearing with AAV: Stories from Syne4
|
|
15:20
|
Eric Shifrut, Tel Aviv University, Israel
CRISPR discovery platforms for engineered T cell therapies
|
|
15:40
|
Marcelo Erlich, Tel Aviv University, Israel
Oncolytic virotherapy: exploiting cancer-induced modifications to cell autonomous immunity
|
|
16:00
|
Adi Barzel, Tel Aviv Univervisty, Israel
In vivo B cell engineering
|
|
16:20
|
Dan Peer, Tel-Aviv University, Israel
The RNA revolution: from Gene Silencing to Gene Editing
|
|
16:40
|
Closing Remarks
|
|
17:00
|
Panel Discussion (Hybrid) - Location: Britannia Building, Room 014
Gene delivery technologies for therapeutic applications
Moderated by Professor Dan Peer
Panelists:
Ronit Satchi-Fainaro, Tel Aviv University, Israel
Laura Sepp-Lorenzino, CSO, Intellia
James McArthur, CEO, Pepgen
Patrick Baumhof, VP, RNA formulation in Curevac
Pete Lutwyche, CEO & President, Genevant
|